Study Of Sunitinib With S-1 And Cisplatin For Gastric Cancer

Phase 1 Completed 27 enrolled Pfizer

NaSingle-groupOpen-labelTreatment

Summary

To assess the maximal tolerated dose (MTD) and overall safety of sunitinib when administered in combination with S-1 and Cisplatin in patients with advanced/metastatic gastric cancer.

Timeline

Start: 2007-11
Primary completion: 2009-07
Completion: 2014-03

Publications

Boku N, Muro K, Machida N, Hashigaki S, Kimura N, Suzuki M, Lechuga M, Miyata Y. Phase I study of sunitinib plus S-1 and cisplatin in Japanese patients with advanced or metastatic gastric cancer. Invest New Drugs. 2014 Apr;32(2):261-70. doi: 10.1007/s10637-013-9948-5. Epub 2013 May 12.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sunitinib	Small molecule	25 mg	Oral
Subject	Sunitinib	Small molecule	37.5 mg	Oral
Subject	Sunitinib	Small molecule	50 mg	Oral
Background	Cisplatin	Other / unclassified	60 mg/m2	—
Background	S-1	Small molecule	80 mg/m2	—

Study Of Sunitinib With S-1 And Cisplatin For Gastric Cancer

Summary

Timeline

Publications

Drugs

Indications